{
    "id": 104,
    "premise": "none",
    "hypothesis": "Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance.",
    "label": "entailment",
    "explanation": "an irreversible inhibitor that is targeted to the HER2 kinase domain\u2026 should overcome trastuzumab resistance that has been induced by a HER2-activating mutation.\nHER2 V777L may cause resistance to  trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain.",
    "results": {
        "semantic validity": false,
        "premise": null,
        "hypothesis": "Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance.",
        "history explanation": [
            "0 iteration: an irreversible inhibitor that is targeted to the HER2 kinase domain\u2026 should overcome trastuzumab resistance that has been induced by a HER2-activating mutation.\nHER2 V777L may cause resistance to  trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain.",
            "1 iteration: An irreversible inhibitor that is targeted to the HER2 kinase domain should overcome trastuzumab resistance that has been induced by a HER2-activating mutation.\nHER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain.\nTargeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor can overcome the resistance caused by the HER2 V777L mutation.",
            "2 iteration: An irreversible inhibitor that is targeted to the HER2 kinase domain should overcome trastuzumab resistance that has been induced by a HER2-activating mutation.\nHER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain.\nTargeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor can overcome the resistance caused by the HER2 V777L mutation.\nOvercoming the resistance caused by the HER2 V777L mutation implies overcoming treatment resistance.",
            "3 iteration: An irreversible inhibitor that is targeted to the HER2 kinase domain should overcome trastuzumab resistance that has been induced by a HER2-activating mutation.\nHER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain.\nTargeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor can overcome the resistance caused by the HER2 V777L mutation, and this action directly contributes to overcoming treatment resistance.\nOvercoming the resistance caused by the HER2 V777L mutation implies overcoming treatment resistance.",
            "4 iteration: An irreversible inhibitor that is targeted to the HER2 kinase domain should overcome trastuzumab resistance that has been induced by a HER2-activating mutation.\nHER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain.\nTargeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor can directly overcome the resistance caused by the HER2 V777L mutation, and this action directly contributes to overcoming treatment resistance.\nOvercoming the resistance caused by the HER2 V777L mutation implies overcoming treatment resistance.",
            "5 iteration: An irreversible inhibitor that is targeted to the HER2 kinase domain should overcome trastuzumab resistance that has been induced by a HER2-activating mutation.\nHER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain.\nTargeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor can directly overcome the resistance caused by the HER2 V777L mutation, and this action directly contributes to overcoming treatment resistance.\nOvercoming the resistance caused by the HER2 V777L mutation implies overcoming treatment resistance.",
            "6 iteration: An irreversible inhibitor that is targeted to the HER2 kinase domain should overcome trastuzumab resistance that has been induced by a HER2-activating mutation.\nHER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain.\nTargeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor can directly overcome the resistance caused by the HER2 V777L mutation, and this action is a necessary step in overcoming treatment resistance.\nDirectly overcoming the resistance caused by the HER2 V777L mutation implies overcoming treatment resistance.",
            "7 iteration: An irreversible inhibitor that is targeted to the HER2 kinase domain should overcome trastuzumab resistance that has been induced by a HER2-activating mutation.\nHER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain.\nTargeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor can directly overcome the resistance caused by the HER2 V777L mutation, and this action is a necessary step in overcoming treatment resistance.\nDirectly overcoming the resistance caused by the HER2 V777L mutation implies overcoming treatment resistance.\nTargeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor is specifically aimed at overcoming the resistance caused by the HER2 V777L mutation, which is a critical factor in overcoming treatment resistance.",
            "8 iteration: An irreversible inhibitor that is targeted to the HER2 kinase domain should overcome trastuzumab resistance that has been induced by a HER2-activating mutation.\nHER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain.\nTargeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor can directly overcome the resistance caused by the HER2 V777L mutation, and this action is a necessary step in overcoming treatment resistance.\nDirectly overcoming the resistance caused by the HER2 V777L mutation implies overcoming treatment resistance.\nTargeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor is specifically aimed at overcoming the resistance caused by the HER2 V777L mutation, which is a critical factor in overcoming treatment resistance.",
            "9 iteration: An irreversible inhibitor that is targeted to the HER2 kinase domain should overcome trastuzumab resistance that has been induced by a HER2-activating mutation.\nHER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain.\nTargeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor can directly overcome the resistance caused by the HER2 V777L mutation, and this action is a necessary step in overcoming treatment resistance.\nDirectly overcoming the resistance caused by the HER2 V777L mutation is a critical factor in overcoming treatment resistance.\nTargeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor is specifically aimed at overcoming the resistance caused by the HER2 V777L mutation, which is a critical factor in overcoming treatment resistance.",
            "10 iteration: An irreversible inhibitor that is targeted to the HER2 kinase domain should overcome trastuzumab resistance that has been induced by a HER2-activating mutation.\nHER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain.\nTargeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor can directly overcome the resistance caused by the HER2 V777L mutation, and this action is a necessary step in overcoming treatment resistance.\nDirectly overcoming the resistance caused by the HER2 V777L mutation is a critical factor in overcoming treatment resistance.\nTargeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor is specifically aimed at overcoming the resistance caused by the HER2 V777L mutation, which is a critical factor in overcoming treatment resistance.\nOvercoming the resistance caused by the HER2 V777L mutation is directly related to overcoming overall treatment resistance."
        ],
        "history semantic validity": [
            "0 iteration: False",
            "1 iteration: False",
            "2 iteration: False",
            "3 iteration: False",
            "4 iteration: False",
            "5 iteration: False",
            "6 iteration: False",
            "7 iteration: False",
            "8 iteration: False",
            "9 iteration: False",
            "10 iteration: False"
        ],
        "history critique output": [
            "0 iteration: {'syntactic validity': True, 'error code': '(* Explanation 1 provides a scenario where an irreversible inhibitor targeted to the HER2 kinase domain overcomes trastuzumab resistance induced by a HER2-activating mutation. *)\\n(* We can relate this to the hypothesis by considering the targeting of the HER V777L mutation with an irreversible tyrosine kinase inhibitor. *)\\n(* Explanation 2 indicates that HER2 V777L causes resistance to trastuzumab, which aligns with the treatment resistance in the premise. *)\\n(* Therefore, targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor should overcome the treatment resistance. *)\\nthen have \"\u2203x e. Targeting x \u2227 Irreversible_Tyrosine_Kinase_Inhibitor x \u2227 Overcome e \u2227 Agent e x \u2227 Patient e y\" sledgehammer', 'solving time': 103.84592914581299, 'proof tactics': [], 'code': 'theory clinical_104_0\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Irreversible_Inhibitor :: \"entity \u21d2 bool\"\\n  Targeted_To :: \"entity \u21d2 entity \u21d2 bool\"\\n  HER2_Kinase_Domain :: \"entity \u21d2 bool\"\\n  Overcome :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Trastuzumab_Resistance :: \"entity \u21d2 bool\"\\n  Induced_By :: \"entity \u21d2 event \u21d2 bool\"\\n  HER2_Activating_Mutation :: \"event \u21d2 bool\"\\n  HER2_V777L :: \"entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Bind :: \"event \u21d2 bool\"\\n  Extracellular_Kinase_Domain :: \"entity \u21d2 bool\"\\n  Mutation_In :: \"event \u21d2 bool\"\\n  Intracellular_Kinase_Domain :: \"event \u21d2 bool\"\\n  Targeting :: \"entity \u21d2 bool\"\\n  HER_V777L_Mutation :: \"entity \u21d2 bool\"\\n  Irreversible_Tyrosine_Kinase_Inhibitor :: \"entity \u21d2 bool\"\\n  Treatment_Resistance :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: An irreversible inhibitor that is targeted to the HER2 kinase domain should overcome trastuzumab resistance that has been induced by a HER2-activating mutation. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. Irreversible_Inhibitor x \u2227 Targeted_To x y \u2227 HER2_Kinase_Domain y \u2227 Overcome e1 \u2227 Agent e1 x \u2227 Trastuzumab_Resistance z \u2227 Induced_By z e2 \u2227 HER2_Activating_Mutation e2\"\\n\\n(* Explanation 2: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2 e3. HER2_V777L x \u2227 Resistance y \u2227 Trastuzumab z \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Bind e2 \u2227 Agent e2 z \u2227 Extracellular_Kinase_Domain y \u2227 Mutation_In e3 \u2227 Intracellular_Kinase_Domain e3\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"HER_V777L_Mutation y \u2227 Treatment_Resistance y\"\\n  (* Hypothesis: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance. *)\\n  shows \"\u2203x e. Targeting x \u2227 Irreversible_Tyrosine_Kinase_Inhibitor x \u2227 Overcome e \u2227 Agent e x \u2227 Patient e y\"\\nproof -\\n  (* From the premise, we have known information about HER_V777L_Mutation and Treatment_Resistance. *)\\n  from asm have \"HER_V777L_Mutation y \u2227 Treatment_Resistance y\" <ATP>\\n  (* Explanation 1 provides a scenario where an irreversible inhibitor targeted to the HER2 kinase domain overcomes trastuzumab resistance induced by a HER2-activating mutation. *)\\n  (* We can relate this to the hypothesis by considering the targeting of the HER V777L mutation with an irreversible tyrosine kinase inhibitor. *)\\n  (* Explanation 2 indicates that HER2 V777L causes resistance to trastuzumab, which aligns with the treatment resistance in the premise. *)\\n  (* Therefore, targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor should overcome the treatment resistance. *)\\n  then have \"\u2203x e. Targeting x \u2227 Irreversible_Tyrosine_Kinase_Inhibitor x \u2227 Overcome e \u2227 Agent e x \u2227 Patient e y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: an irreversible inhibitor is targeted to the HER2 kinase domain (from Explanatory Sentence 1)\\nB: trastuzumab resistance is overcome (from Explanatory Sentence 1)\\nC: HER2 V777L causes resistance to trastuzumab (from Explanatory Sentence 2)\\nD: trastuzumab binds to the extracellular kinase domain (from Explanatory Sentence 2)\\nE: the mutation is in the intracellular kinase domain (from Explanatory Sentence 2)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(an irreversible inhibitor is targeted to the HER2 kinase domain, trastuzumab resistance is overcome)\\n--------\\nImplies(C, D)\\nImplies(HER2 V777L causes resistance to trastuzumab, trastuzumab binds to the extracellular kinase domain)\\n--------\\nImplies(C, E)\\nImplies(HER2 V777L causes resistance to trastuzumab, the mutation is in the intracellular kinase domain)\\n--------\\n\\nDerived Implications:\\n'}",
            "1 iteration: {'syntactic validity': True, 'error code': '(* Explanation 3 provides a logical relation Implies(F, G), which states that targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor can overcome the resistance caused by the HER2 V777L mutation. *)\\n(* Since we have HER_V777L_Mutation y, Tyrosine_Kinase_Inhibitor x, and Irreversible x, we can infer the existence of an event e that satisfies the hypothesis. *)\\nthen have \"\u2203e. Targeting x \u2227 Overcome e \u2227 Agent e x \u2227 Patient e y \u2227 Treatment_Resistance y\" sledgehammer', 'solving time': 103.51322555541992, 'proof tactics': [], 'code': 'theory clinical_104_1\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  Irreversible :: \"entity \u21d2 bool\"\\n  TargetedTo :: \"entity \u21d2 entity \u21d2 bool\"\\n  HER2_Kinase_Domain :: \"entity \u21d2 bool\"\\n  Overcome :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Trastuzumab_Resistance :: \"entity \u21d2 bool\"\\n  InducedBy :: \"entity \u21d2 event \u21d2 bool\"\\n  HER2_Activating_Mutation :: \"event \u21d2 bool\"\\n  HER2_V777L :: \"entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  Extracellular_Kinase_Domain :: \"entity \u21d2 bool\"\\n  Intracellular_Kinase_Domain :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Resistance :: \"event \u21d2 entity \u21d2 bool\"\\n  Bind :: \"event \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Targeting :: \"entity \u21d2 bool\"\\n  HER_V777L_Mutation :: \"entity \u21d2 bool\"\\n  Tyrosine_Kinase_Inhibitor :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: An irreversible inhibitor that is targeted to the HER2 kinase domain should overcome trastuzumab resistance that has been induced by a HER2-activating mutation. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. Inhibitor x \u2227 Irreversible x \u2227 TargetedTo x y \u2227 HER2_Kinase_Domain y \u2227 Overcome e1 \u2227 Agent e1 x \u2227 Trastuzumab_Resistance z \u2227 InducedBy z e2 \u2227 HER2_Activating_Mutation e2\"\\n\\n(* Explanation 2: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. HER2_V777L x \u2227 Trastuzumab y \u2227 Extracellular_Kinase_Domain z \u2227 Intracellular_Kinase_Domain z \u2227 Cause e1 \u2227 Agent e1 x \u2227 Resistance e1 y \u2227 Bind e2 \u2227 Agent e2 y \u2227 Patient e2 z \u2227 In x z\"\\n\\n(* Explanation 3: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor can overcome the resistance caused by the HER2 V777L mutation. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. Targeting x \u2227 HER_V777L_Mutation y \u2227 Tyrosine_Kinase_Inhibitor x \u2227 Irreversible x \u2227 Overcome e1 \u2227 Agent e1 x \u2227 Resistance e1 z \u2227 Cause e2 \u2227 Agent e2 y \u2227 Patient e2 z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"HER_V777L_Mutation y \u2227 Tyrosine_Kinase_Inhibitor x \u2227 Irreversible x\"\\n  (* Hypothesis: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance. *)\\n  shows \"\u2203x y e. Targeting x \u2227 HER_V777L_Mutation y \u2227 Tyrosine_Kinase_Inhibitor x \u2227 Irreversible x \u2227 Overcome e \u2227 Agent e x \u2227 Patient e y \u2227 Treatment_Resistance y\"\\nproof -\\n  (* From the premise, we have the known information about HER_V777L_Mutation, Tyrosine_Kinase_Inhibitor, and Irreversible. *)\\n  from asm have \"HER_V777L_Mutation y \u2227 Tyrosine_Kinase_Inhibitor x \u2227 Irreversible x\" <ATP>\\n  (* Explanation 3 provides a logical relation Implies(F, G), which states that targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor can overcome the resistance caused by the HER2 V777L mutation. *)\\n  (* Since we have HER_V777L_Mutation y, Tyrosine_Kinase_Inhibitor x, and Irreversible x, we can infer the existence of an event e that satisfies the hypothesis. *)\\n  then have \"\u2203e. Targeting x \u2227 Overcome e \u2227 Agent e x \u2227 Patient e y \u2227 Treatment_Resistance y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: irreversible inhibitor is targeted to the HER2 kinase domain (from Explanatory Sentence 1)\\nB: overcome trastuzumab resistance induced by a HER2-activating mutation (from Explanatory Sentence 1)\\nC: HER2 V777L causes resistance to trastuzumab (from Explanatory Sentence 2)\\nD: trastuzumab binds to the extracellular kinase domain (from Explanatory Sentence 2)\\nE: mutation is in the intracellular kinase domain (from Explanatory Sentence 2)\\nF: targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor (from Explanatory Sentence 3)\\nG: overcome resistance caused by the HER2 V777L mutation (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(irreversible inhibitor is targeted to the HER2 kinase domain, overcome trastuzumab resistance induced by a HER2-activating mutation)\\n--------\\nImplies(C, D)\\nImplies(HER2 V777L causes resistance to trastuzumab, trastuzumab binds to the extracellular kinase domain)\\n--------\\nImplies(C, E)\\nImplies(HER2 V777L causes resistance to trastuzumab, mutation is in the intracellular kinase domain)\\n--------\\nImplies(F, G)\\nImplies(targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor, overcome resistance caused by the HER2 V777L mutation)\\n--------\\n\\nDerived Implications:\\n'}",
            "2 iteration: {'syntactic validity': True, 'error code': '(* Explanation 3 provides that targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor can overcome the resistance caused by the HER2 V777L mutation. *)\\n(* This is represented by the logical relation Implies(F, G). *)\\n(* Explanation 4 states that overcoming the resistance caused by the HER2 V777L mutation implies overcoming treatment resistance, represented by Implies(G, H). *)\\n(* Therefore, from F, we can infer H. *)\\nthen have \"\u2203x y e. Targeting x \u2227 HERV777LMutation y \u2227 TyrosineKinaseInhibitor x \u2227 Irreversible x \u2227 Overcome e \u2227 Agent e x \u2227 Patient e y \u2227 TreatmentResistance e\" sledgehammer', 'solving time': 103.43972897529602, 'proof tactics': [], 'code': 'theory clinical_104_2\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  Irreversible :: \"entity \u21d2 bool\"\\n  TargetedTo :: \"entity \u21d2 entity \u21d2 bool\"\\n  HER2KinaseDomain :: \"entity \u21d2 bool\"\\n  Overcome :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  TrastuzumabResistance :: \"entity \u21d2 bool\"\\n  InducedBy :: \"entity \u21d2 event \u21d2 bool\"\\n  HER2ActivatingMutation :: \"event \u21d2 bool\"\\n  HER2V777L :: \"entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  ExtracellularKinaseDomain :: \"entity \u21d2 bool\"\\n  Binds :: \"event \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  IntracellularKinaseDomain :: \"entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Targeting :: \"entity \u21d2 bool\"\\n  HERV777LMutation :: \"entity \u21d2 bool\"\\n  TyrosineKinaseInhibitor :: \"entity \u21d2 bool\"\\n  CausedBy :: \"entity \u21d2 event \u21d2 bool\"\\n  HER2V777LMutation :: \"event \u21d2 bool\"\\n  TreatmentResistance :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: An irreversible inhibitor that is targeted to the HER2 kinase domain should overcome trastuzumab resistance that has been induced by a HER2-activating mutation. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. Inhibitor x \u2227 Irreversible x \u2227 TargetedTo x y \u2227 HER2KinaseDomain y \u2227 Overcome e1 \u2227 Agent e1 x \u2227 TrastuzumabResistance z \u2227 InducedBy z e2 \u2227 HER2ActivatingMutation e2\"\\n\\n(* Explanation 2: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain. *)\\naxiomatization where\\n  explanation_2_1: \"\u2203x y e. HER2V777L x \u2227 Resistance y \u2227 Trastuzumab y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\"\\n\\naxiomatization where\\n  explanation_2_2: \"\u2203x y e. Trastuzumab x \u2227 ExtracellularKinaseDomain y \u2227 Binds e \u2227 Agent e x \u2227 Patient e y\"\\n\\naxiomatization where\\n  explanation_2_3: \"\u2203x y. Mutation x \u2227 IntracellularKinaseDomain y \u2227 In x y\"\\n\\n(* Explanation 3: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor can overcome the resistance caused by the HER2 V777L mutation. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. Targeting x \u2227 HERV777LMutation y \u2227 TyrosineKinaseInhibitor x \u2227 Irreversible x \u2227 Overcome e1 \u2227 Agent e1 x \u2227 Resistance z \u2227 CausedBy z e2 \u2227 HER2V777LMutation e2\"\\n\\n(* Explanation 4: Overcoming the resistance caused by the HER2 V777L mutation implies overcoming treatment resistance. *)\\naxiomatization where\\n  explanation_4: \"\u2200x y e1 e2. Resistance x \u2227 HER2V777LMutation y \u2227 CausedBy x y \u2227 Overcome e1 \u2227 Agent e1 x \u27f6 (Overcome e2 \u2227 TreatmentResistance e2)\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"HERV777LMutation y \u2227 TreatmentResistance e\"\\n  (* Hypothesis: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance. *)\\n  shows \"\u2203x y e. Targeting x \u2227 HERV777LMutation y \u2227 TyrosineKinaseInhibitor x \u2227 Irreversible x \u2227 Overcome e \u2227 Agent e x \u2227 Patient e y \u2227 TreatmentResistance e\"\\nproof -\\n  (* From the known information, we have HERV777LMutation y and TreatmentResistance e. *)\\n  from asm have \"HERV777LMutation y \u2227 TreatmentResistance e\" <ATP>\\n  (* Explanation 3 provides that targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor can overcome the resistance caused by the HER2 V777L mutation. *)\\n  (* This is represented by the logical relation Implies(F, G). *)\\n  (* Explanation 4 states that overcoming the resistance caused by the HER2 V777L mutation implies overcoming treatment resistance, represented by Implies(G, H). *)\\n  (* Therefore, from F, we can infer H. *)\\n  then have \"\u2203x y e. Targeting x \u2227 HERV777LMutation y \u2227 TyrosineKinaseInhibitor x \u2227 Irreversible x \u2227 Overcome e \u2227 Agent e x \u2227 Patient e y \u2227 TreatmentResistance e\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: irreversible inhibitor targeted to the HER2 kinase domain (from Explanatory Sentence 1)\\nB: overcome trastuzumab resistance induced by a HER2-activating mutation (from Explanatory Sentence 1)\\nC: HER2 V777L causes resistance to trastuzumab (from Explanatory Sentence 2)\\nD: trastuzumab binds to the extracellular kinase domain (from Explanatory Sentence 2)\\nE: mutation is in the intracellular kinase domain (from Explanatory Sentence 2)\\nF: targeting the HER2 V777L mutation with an irreversible tyrosine kinase inhibitor (from Explanatory Sentence 3)\\nG: overcome resistance caused by the HER2 V777L mutation (from Explanatory Sentence 3)\\nH: overcome treatment resistance (from Explanatory Sentence 4)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(irreversible inhibitor targeted to the HER2 kinase domain, overcome trastuzumab resistance induced by a HER2-activating mutation)\\n--------\\nAnd(C, D, E)\\nC & D & E\\n--------\\nImplies(F, G)\\nImplies(targeting the HER2 V777L mutation with an irreversible tyrosine kinase inhibitor, overcome resistance caused by the HER2 V777L mutation)\\n--------\\nImplies(G, H)\\nImplies(overcome resistance caused by the HER2 V777L mutation, overcome treatment resistance)\\n--------\\n\\nDerived Implications:\\nImplies(Not(A), C)\\nImplies(Not(irreversible inhibitor targeted to the HER2 kinase domain), HER2 V777L causes resistance to trastuzumab)\\n--------\\nImplies(Not(E), H)\\nImplies(Not(mutation is in the intracellular kinase domain), overcome treatment resistance)\\n--------\\nImplies(Not(D), G)\\nImplies(Not(trastuzumab binds to the extracellular kinase domain), overcome resistance caused by the HER2 V777L mutation)\\n--------\\nImplies(Not(C), Not(F))\\nImplies(Not(HER2 V777L causes resistance to trastuzumab), Not(targeting the HER2 V777L mutation with an irreversible tyrosine kinase inhibitor))\\n--------\\nImplies(C, E)\\nImplies(HER2 V777L causes resistance to trastuzumab, mutation is in the intracellular kinase domain)\\n--------\\nImplies(Not(E), Not(H))\\nImplies(Not(mutation is in the intracellular kinase domain), Not(overcome treatment resistance))\\n--------\\nImplies(C, D)\\nImplies(HER2 V777L causes resistance to trastuzumab, trastuzumab binds to the extracellular kinase domain)\\n--------\\nImplies(Not(D), Not(E))\\nImplies(Not(trastuzumab binds to the extracellular kinase domain), Not(mutation is in the intracellular kinase domain))\\n--------\\nImplies(B, D)\\nImplies(overcome trastuzumab resistance induced by a HER2-activating mutation, trastuzumab binds to the extracellular kinase domain)\\n--------\\nImplies(Not(C), G)\\nImplies(Not(HER2 V777L causes resistance to trastuzumab), overcome resistance caused by the HER2 V777L mutation)\\n--------\\nImplies(B, C)\\nImplies(overcome trastuzumab resistance induced by a HER2-activating mutation, HER2 V777L causes resistance to trastuzumab)\\n--------\\nImplies(Not(D), A)\\nImplies(Not(trastuzumab binds to the extracellular kinase domain), irreversible inhibitor targeted to the HER2 kinase domain)\\n--------\\nImplies(Not(E), D)\\nImplies(Not(mutation is in the intracellular kinase domain), trastuzumab binds to the extracellular kinase domain)\\n--------\\nImplies(Not(E), Not(D))\\nImplies(Not(mutation is in the intracellular kinase domain), Not(trastuzumab binds to the extracellular kinase domain))\\n--------\\nImplies(Not(D), E)\\nImplies(Not(trastuzumab binds to the extracellular kinase domain), mutation is in the intracellular kinase domain)\\n--------\\nImplies(Not(E), C)\\nImplies(Not(mutation is in the intracellular kinase domain), HER2 V777L causes resistance to trastuzumab)\\n--------\\nImplies(Not(E), Not(G))\\nImplies(Not(mutation is in the intracellular kinase domain), Not(overcome resistance caused by the HER2 V777L mutation))\\n--------\\nImplies(H, E)\\nImplies(overcome treatment resistance, mutation is in the intracellular kinase domain)\\n--------\\nImplies(Not(C), A)\\nImplies(Not(HER2 V777L causes resistance to trastuzumab), irreversible inhibitor targeted to the HER2 kinase domain)\\n--------\\nImplies(H, D)\\nImplies(overcome treatment resistance, trastuzumab binds to the extracellular kinase domain)\\n--------\\nImplies(Not(E), Not(C))\\nImplies(Not(mutation is in the intracellular kinase domain), Not(HER2 V777L causes resistance to trastuzumab))\\n--------\\nImplies(Not(E), Not(B))\\nImplies(Not(mutation is in the intracellular kinase domain), Not(overcome trastuzumab resistance induced by a HER2-activating mutation))\\n--------\\nImplies(Not(D), Not(A))\\nImplies(Not(trastuzumab binds to the extracellular kinase domain), Not(irreversible inhibitor targeted to the HER2 kinase domain))\\n--------\\nImplies(Not(D), H)\\nImplies(Not(trastuzumab binds to the extracellular kinase domain), overcome treatment resistance)\\n--------\\nImplies(H, C)\\nImplies(overcome treatment resistance, HER2 V777L causes resistance to trastuzumab)\\n--------\\nImplies(A, E)\\nImplies(irreversible inhibitor targeted to the HER2 kinase domain, mutation is in the intracellular kinase domain)\\n--------\\nImplies(Not(D), Not(H))\\nImplies(Not(trastuzumab binds to the extracellular kinase domain), Not(overcome treatment resistance))\\n--------\\nImplies(Not(B), E)\\nImplies(Not(overcome trastuzumab resistance induced by a HER2-activating mutation), mutation is in the intracellular kinase domain)\\n--------\\nImplies(Not(C), B)\\nImplies(Not(HER2 V777L causes resistance to trastuzumab), overcome trastuzumab resistance induced by a HER2-activating mutation)\\n--------\\nImplies(Not(C), H)\\nImplies(Not(HER2 V777L causes resistance to trastuzumab), overcome treatment resistance)\\n--------\\nImplies(Not(E), F)\\nImplies(Not(mutation is in the intracellular kinase domain), targeting the HER2 V777L mutation with an irreversible tyrosine kinase inhibitor)\\n--------\\nImplies(Not(D), D)\\nImplies(Not(trastuzumab binds to the extracellular kinase domain), trastuzumab binds to the extracellular kinase domain)\\n--------\\nImplies(Not(C), Not(E))\\nImplies(Not(HER2 V777L causes resistance to trastuzumab), Not(mutation is in the intracellular kinase domain))\\n--------\\nImplies(Not(H), E)\\nImplies(Not(overcome treatment resistance), mutation is in the intracellular kinase domain)\\n--------\\nImplies(Not(H), D)\\nImplies(Not(overcome treatment resistance), trastuzumab binds to the extracellular kinase domain)\\n--------\\nImplies(Not(D), C)\\nImplies(Not(trastuzumab binds to the extracellular kinase domain), HER2 V777L causes resistance to trastuzumab)\\n--------\\nImplies(F, H)\\nImplies(targeting the HER2 V777L mutation with an irreversible tyrosine kinase inhibitor, overcome treatment resistance)\\n--------\\nImplies(Not(D), Not(G))\\nImplies(Not(trastuzumab binds to the extracellular kinase domain), Not(overcome resistance caused by the HER2 V777L mutation))\\n--------\\nImplies(Not(G), E)\\nImplies(Not(overcome resistance caused by the HER2 V777L mutation), mutation is in the intracellular kinase domain)\\n--------\\nImplies(Not(C), E)\\nImplies(Not(HER2 V777L causes resistance to trastuzumab), mutation is in the intracellular kinase domain)\\n--------\\nImplies(G, E)\\nImplies(overcome resistance caused by the HER2 V777L mutation, mutation is in the intracellular kinase domain)\\n--------\\nImplies(Not(D), Not(C))\\nImplies(Not(trastuzumab binds to the extracellular kinase domain), Not(HER2 V777L causes resistance to trastuzumab))\\n--------\\nImplies(Not(D), Not(B))\\nImplies(Not(trastuzumab binds to the extracellular kinase domain), Not(overcome trastuzumab resistance induced by a HER2-activating mutation))\\n--------\\nImplies(Not(C), D)\\nImplies(Not(HER2 V777L causes resistance to trastuzumab), trastuzumab binds to the extracellular kinase domain)\\n--------\\nImplies(G, D)\\nImplies(overcome resistance caused by the HER2 V777L mutation, trastuzumab binds to the extracellular kinase domain)\\n--------\\nImplies(Not(E), Not(F))\\nImplies(Not(mutation is in the intracellular kinase domain), Not(targeting the HER2 V777L mutation with an irreversible tyrosine kinase inhibitor))\\n--------\\nImplies(A, D)\\nImplies(irreversible inhibitor targeted to the HER2 kinase domain, trastuzumab binds to the extracellular kinase domain)\\n--------\\nImplies(D, E)\\nImplies(trastuzumab binds to the extracellular kinase domain, mutation is in the intracellular kinase domain)\\n--------\\nImplies(Not(C), C)\\nImplies(Not(HER2 V777L causes resistance to trastuzumab), HER2 V777L causes resistance to trastuzumab)\\n--------\\nImplies(G, C)\\nImplies(overcome resistance caused by the HER2 V777L mutation, HER2 V777L causes resistance to trastuzumab)\\n--------\\nImplies(A, C)\\nImplies(irreversible inhibitor targeted to the HER2 kinase domain, HER2 V777L causes resistance to trastuzumab)\\n--------\\nImplies(Not(B), D)\\nImplies(Not(overcome trastuzumab resistance induced by a HER2-activating mutation), trastuzumab binds to the extracellular kinase domain)\\n--------\\nImplies(Not(C), Not(G))\\nImplies(Not(HER2 V777L causes resistance to trastuzumab), Not(overcome resistance caused by the HER2 V777L mutation))\\n--------\\nImplies(D, C)\\nImplies(trastuzumab binds to the extracellular kinase domain, HER2 V777L causes resistance to trastuzumab)\\n--------\\nImplies(E, D)\\nImplies(mutation is in the intracellular kinase domain, trastuzumab binds to the extracellular kinase domain)\\n--------\\nImplies(Not(B), C)\\nImplies(Not(overcome trastuzumab resistance induced by a HER2-activating mutation), HER2 V777L causes resistance to trastuzumab)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(HER2 V777L causes resistance to trastuzumab), Not(irreversible inhibitor targeted to the HER2 kinase domain))\\n--------\\nImplies(F, E)\\nImplies(targeting the HER2 V777L mutation with an irreversible tyrosine kinase inhibitor, mutation is in the intracellular kinase domain)\\n--------\\nImplies(Not(E), B)\\nImplies(Not(mutation is in the intracellular kinase domain), overcome trastuzumab resistance induced by a HER2-activating mutation)\\n--------\\nImplies(Not(A), E)\\nImplies(Not(irreversible inhibitor targeted to the HER2 kinase domain), mutation is in the intracellular kinase domain)\\n--------\\nImplies(F, D)\\nImplies(targeting the HER2 V777L mutation with an irreversible tyrosine kinase inhibitor, trastuzumab binds to the extracellular kinase domain)\\n--------\\nImplies(Not(A), D)\\nImplies(Not(irreversible inhibitor targeted to the HER2 kinase domain), trastuzumab binds to the extracellular kinase domain)\\n--------\\nImplies(Not(C), Not(B))\\nImplies(Not(HER2 V777L causes resistance to trastuzumab), Not(overcome trastuzumab resistance induced by a HER2-activating mutation))\\n--------\\nImplies(Not(E), G)\\nImplies(Not(mutation is in the intracellular kinase domain), overcome resistance caused by the HER2 V777L mutation)\\n--------\\nImplies(Not(C), Not(H))\\nImplies(Not(HER2 V777L causes resistance to trastuzumab), Not(overcome treatment resistance))\\n--------\\nImplies(Not(D), F)\\nImplies(Not(trastuzumab binds to the extracellular kinase domain), targeting the HER2 V777L mutation with an irreversible tyrosine kinase inhibitor)\\n--------\\nImplies(Not(F), E)\\nImplies(Not(targeting the HER2 V777L mutation with an irreversible tyrosine kinase inhibitor), mutation is in the intracellular kinase domain)\\n--------\\nImplies(Not(F), D)\\nImplies(Not(targeting the HER2 V777L mutation with an irreversible tyrosine kinase inhibitor), trastuzumab binds to the extracellular kinase domain)\\n--------\\nImplies(Not(H), C)\\nImplies(Not(overcome treatment resistance), HER2 V777L causes resistance to trastuzumab)\\n--------\\nImplies(Not(F), C)\\nImplies(Not(targeting the HER2 V777L mutation with an irreversible tyrosine kinase inhibitor), HER2 V777L causes resistance to trastuzumab)\\n--------\\nImplies(Not(G), D)\\nImplies(Not(overcome resistance caused by the HER2 V777L mutation), trastuzumab binds to the extracellular kinase domain)\\n--------\\nImplies(B, E)\\nImplies(overcome trastuzumab resistance induced by a HER2-activating mutation, mutation is in the intracellular kinase domain)\\n--------\\nImplies(Not(G), C)\\nImplies(Not(overcome resistance caused by the HER2 V777L mutation), HER2 V777L causes resistance to trastuzumab)\\n--------\\nImplies(Not(E), A)\\nImplies(Not(mutation is in the intracellular kinase domain), irreversible inhibitor targeted to the HER2 kinase domain)\\n--------\\nImplies(Not(C), Not(D))\\nImplies(Not(HER2 V777L causes resistance to trastuzumab), Not(trastuzumab binds to the extracellular kinase domain))\\n--------\\nImplies(Not(C), F)\\nImplies(Not(HER2 V777L causes resistance to trastuzumab), targeting the HER2 V777L mutation with an irreversible tyrosine kinase inhibitor)\\n--------\\nImplies(Not(E), E)\\nImplies(Not(mutation is in the intracellular kinase domain), mutation is in the intracellular kinase domain)\\n--------\\nImplies(Not(D), Not(F))\\nImplies(Not(trastuzumab binds to the extracellular kinase domain), Not(targeting the HER2 V777L mutation with an irreversible tyrosine kinase inhibitor))\\n--------\\nImplies(Not(H), Not(F))\\nImplies(Not(overcome treatment resistance), Not(targeting the HER2 V777L mutation with an irreversible tyrosine kinase inhibitor))\\n--------\\nImplies(E, C)\\nImplies(mutation is in the intracellular kinase domain, HER2 V777L causes resistance to trastuzumab)\\n--------\\nImplies(Not(D), B)\\nImplies(Not(trastuzumab binds to the extracellular kinase domain), overcome trastuzumab resistance induced by a HER2-activating mutation)\\n--------\\nImplies(F, C)\\nImplies(targeting the HER2 V777L mutation with an irreversible tyrosine kinase inhibitor, HER2 V777L causes resistance to trastuzumab)\\n--------\\nImplies(Not(E), Not(A))\\nImplies(Not(mutation is in the intracellular kinase domain), Not(irreversible inhibitor targeted to the HER2 kinase domain))\\n--------\\n'}",
            "3 iteration: {'syntactic validity': True, 'error code': '(* There is a logical relation Implies(F, G), Implies(targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor, overcome resistance caused by the HER2 V777L mutation) *)\\n(* F is from explanatory sentence 3, G is from explanatory sentence 3. *)\\n(* We already have Targeting x, HER_V777L_Mutation y, Tyrosine_Kinase_Inhibitor x, and Irreversible x, so we can infer overcome resistance caused by the HER2 V777L mutation. *)\\nthen have \"Overcome e \u2227 Agent e x \u2227 Patient e y\" sledgehammer', 'solving time': 103.50510883331299, 'proof tactics': [], 'code': 'theory clinical_104_3\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  Irreversible :: \"entity \u21d2 bool\"\\n  TargetedTo :: \"entity \u21d2 entity \u21d2 bool\"\\n  HER2_Kinase_Domain :: \"entity \u21d2 bool\"\\n  Overcome :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Trastuzumab_Resistance :: \"entity \u21d2 bool\"\\n  InducedBy :: \"entity \u21d2 entity \u21d2 bool\"\\n  HER2_V777L :: \"entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Targeting :: \"entity \u21d2 bool\"\\n  HER_V777L_Mutation :: \"entity \u21d2 bool\"\\n  Tyrosine_Kinase_Inhibitor :: \"entity \u21d2 bool\"\\n  HER2_V777L_Mutation :: \"entity \u21d2 bool\"\\n  Contribute :: \"event \u21d2 entity \u21d2 bool\"\\n  Treatment_Resistance :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: An irreversible inhibitor that is targeted to the HER2 kinase domain should overcome trastuzumab resistance that has been induced by a HER2-activating mutation. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. Inhibitor x \u2227 Irreversible x \u2227 TargetedTo x y \u2227 HER2_Kinase_Domain y \u2227 Overcome e \u2227 Agent e x \u2227 Trastuzumab_Resistance z \u2227 InducedBy z HER2_Activating_Mutation\"\\n\\n(* Explanation 2: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y e. HER2_V777L x \u2227 Resistance y \u2227 Trastuzumab y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\"\\n\\n(* Explanation 3: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor can overcome the resistance caused by the HER2 V777L mutation, and this action directly contributes to overcoming treatment resistance. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. Targeting x \u2227 HER_V777L_Mutation y \u2227 Tyrosine_Kinase_Inhibitor x \u2227 Irreversible x \u2227 Resistance z \u2227 HER2_V777L_Mutation z \u2227 Cause e1 \u2227 Agent e1 z \u2227 Patient e1 y \u2227 Overcome e2 \u2227 Agent e2 x \u2227 Patient e2 z \u2227 Contribute e2 y \u2227 Treatment_Resistance y\"\\n\\n(* Explanation 4: Overcoming the resistance caused by the HER2 V777L mutation implies overcoming treatment resistance. *)\\naxiomatization where\\n  explanation_4: \"\u2200x y e1 e2. Resistance x \u2227 HER2_V777L_Mutation x \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Overcome e2 \u2227 Agent e2 x \u2227 Treatment_Resistance y \u27f6 Overcome e2 \u2227 Treatment_Resistance y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Targeting x \u2227 HER_V777L_Mutation y \u2227 Tyrosine_Kinase_Inhibitor x \u2227 Irreversible x \u2227 Treatment_Resistance y\"\\n  (* Hypothesis: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance. *)\\n  shows \"\u2203x y e. Targeting x \u2227 HER_V777L_Mutation y \u2227 Tyrosine_Kinase_Inhibitor x \u2227 Irreversible x \u2227 Overcome e \u2227 Agent e x \u2227 Patient e y \u2227 Treatment_Resistance y\"\\nproof -\\n  (* From the premise, we have known information about targeting, HER V777L mutation, tyrosine kinase inhibitor, irreversibility, and treatment resistance. *)\\n  from asm have \"Targeting x \u2227 HER_V777L_Mutation y \u2227 Tyrosine_Kinase_Inhibitor x \u2227 Irreversible x \u2227 Treatment_Resistance y\" <ATP>\\n  (* There is a logical relation Implies(F, G), Implies(targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor, overcome resistance caused by the HER2 V777L mutation) *)\\n  (* F is from explanatory sentence 3, G is from explanatory sentence 3. *)\\n  (* We already have Targeting x, HER_V777L_Mutation y, Tyrosine_Kinase_Inhibitor x, and Irreversible x, so we can infer overcome resistance caused by the HER2 V777L mutation. *)\\n  then have \"Overcome e \u2227 Agent e x \u2227 Patient e y\" <ATP>\\n  (* There is a logical relation Implies(I, J), Implies(overcoming the resistance caused by the HER2 V777L mutation, overcoming treatment resistance) *)\\n  (* I is from explanatory sentence 4, J is from explanatory sentence 4. *)\\n  (* We already have Overcome e, so we can infer overcoming treatment resistance. *)\\n  then have \"Overcome e \u2227 Treatment_Resistance y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: irreversible inhibitor targeted to the HER2 kinase domain (from Explanatory Sentence 1)\\nB: overcome trastuzumab resistance induced by a HER2-activating mutation (from Explanatory Sentence 1)\\nC: HER2 V777L causes resistance to trastuzumab (from Explanatory Sentence 2)\\nD: trastuzumab binds to the extracellular kinase domain (from Explanatory Sentence 2)\\nE: mutation is in the intracellular kinase domain (from Explanatory Sentence 2)\\nF: targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor (from Explanatory Sentence 3)\\nG: overcome resistance caused by the HER2 V777L mutation (from Explanatory Sentence 3)\\nH: directly contributes to overcoming treatment resistance (from Explanatory Sentence 3)\\nI: overcoming the resistance caused by the HER2 V777L mutation (from Explanatory Sentence 4)\\nJ: overcoming treatment resistance (from Explanatory Sentence 4)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(irreversible inhibitor targeted to the HER2 kinase domain, overcome trastuzumab resistance induced by a HER2-activating mutation)\\n--------\\nImplies(C, D)\\nImplies(HER2 V777L causes resistance to trastuzumab, trastuzumab binds to the extracellular kinase domain)\\n--------\\nImplies(C, E)\\nImplies(HER2 V777L causes resistance to trastuzumab, mutation is in the intracellular kinase domain)\\n--------\\nImplies(F, G)\\nImplies(targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor, overcome resistance caused by the HER2 V777L mutation)\\n--------\\nImplies(G, H)\\nImplies(overcome resistance caused by the HER2 V777L mutation, directly contributes to overcoming treatment resistance)\\n--------\\nImplies(I, J)\\nImplies(overcoming the resistance caused by the HER2 V777L mutation, overcoming treatment resistance)\\n--------\\n\\nDerived Implications:\\nImplies(F, H)\\nImplies(targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor, directly contributes to overcoming treatment resistance)\\n--------\\nImplies(Not(H), Not(F))\\nImplies(Not(directly contributes to overcoming treatment resistance), Not(targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor))\\n--------\\n'}",
            "4 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_104_4\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  Irreversible :: \"entity \u21d2 bool\"\\n  TargetedTo :: \"entity \u21d2 entity \u21d2 bool\"\\n  HER2KinaseDomain :: \"entity \u21d2 bool\"\\n  Overcome :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  TrastuzumabResistance :: \"entity \u21d2 bool\"\\n  InducedBy :: \"entity \u21d2 entity \u21d2 bool\"\\n  HER2V777L :: \"entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  ExtracellularKinaseDomain :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  ResistanceTo :: \"event \u21d2 entity \u21d2 bool\"\\n  Bind :: \"event \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  IntracellularKinaseDomain :: \"entity \u21d2 bool\"\\n  Mutation :: \"entity \u21d2 bool\"\\n  Targeting :: \"entity \u21d2 bool\"\\n  HERV777LMutation :: \"entity \u21d2 bool\"\\n  TyrosineKinaseInhibitor :: \"entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  CausedBy :: \"entity \u21d2 entity \u21d2 bool\"\\n  Contribute :: \"event \u21d2 bool\"\\n  OvercomingTreatmentResistance :: \"event \u21d2 bool\"\\n  Implies :: \"event \u21d2 bool\"\\n  HER2ActivatingMutation :: \"entity \u21d2 bool\"  (* Added missing consts definition *)\\n\\n(* Explanation 1: An irreversible inhibitor that is targeted to the HER2 kinase domain should overcome trastuzumab resistance that has been induced by a HER2-activating mutation. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z w e. Inhibitor x \u2227 Irreversible x \u2227 TargetedTo x y \u2227 HER2KinaseDomain y \u2227 Overcome e \u2227 Agent e x \u2227 TrastuzumabResistance z \u2227 InducedBy z w \u2227 HER2ActivatingMutation w\"\\n\\n(* Explanation 2: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. HER2V777L x \u2227 Trastuzumab y \u2227 ExtracellularKinaseDomain z \u2227 Cause e1 \u2227 Agent e1 x \u2227 ResistanceTo e1 y \u2227 Bind e2 \u2227 Agent e2 y \u2227 Patient e2 z \u2227 IntracellularKinaseDomain z \u2227 Mutation x\"\\n\\n(* Explanation 3: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor can directly overcome the resistance caused by the HER2 V777L mutation, and this action directly contributes to overcoming treatment resistance. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. Targeting x \u2227 HERV777LMutation y \u2227 TyrosineKinaseInhibitor x \u2227 Irreversible x \u2227 Overcome e1 \u2227 Agent e1 x \u2227 Resistance z \u2227 CausedBy z y \u2227 Contribute e2 \u2227 Agent e2 x \u2227 OvercomingTreatmentResistance e2\"\\n\\n(* Explanation 4: Overcoming the resistance caused by the HER2 V777L mutation implies overcoming treatment resistance. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y e1. Resistance x \u2227 HER2V777LMutation y \u2227 CausedBy x y \u2227 Overcome e1 \u2227 Agent e1 x \u2227 OvercomingTreatmentResistance e1\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"HERV777LMutation y \u2227 TreatmentResistance y\"\\n  (* Hypothesis: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance. *)\\n  shows \"\u2203x y e. Targeting x \u2227 HERV777LMutation y \u2227 TyrosineKinaseInhibitor x \u2227 Irreversible x \u2227 Overcome e \u2227 Agent e x \u2227 Patient e y \u2227 TreatmentResistance y\"\\nproof -\\n  (* From the premise, we have known information about the HER V777L mutation and treatment resistance. *)\\n  from asm have \"HERV777LMutation y \u2227 TreatmentResistance y\" <ATP>\\n  (* There is a logical relation Implies(G, I), which states that targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor implies overcoming treatment resistance. *)\\n  (* Explanation 3 provides the necessary conditions for G, which includes targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor. *)\\n  (* We can use this to infer that targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance. *)\\n  then have \"\u2203x e. Targeting x \u2227 HERV777LMutation y \u2227 TyrosineKinaseInhibitor x \u2227 Irreversible x \u2227 Overcome e \u2227 Agent e x \u2227 OvercomingTreatmentResistance e\" <ATP>\\n  (* Since we have TreatmentResistance y from the premise, we can conclude the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: irreversible inhibitor targeted to the HER2 kinase domain (from Explanatory Sentence 1)\\nB: overcome trastuzumab resistance induced by a HER2-activating mutation (from Explanatory Sentence 1)\\nC: HER2 V777L mutation (from Explanatory Sentence 2)\\nD: trastuzumab resistance (from Explanatory Sentence 2)\\nE: trastuzumab binds to the extracellular kinase domain (from Explanatory Sentence 2)\\nF: mutation in the intracellular kinase domain (from Explanatory Sentence 2)\\nG: targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor (from Explanatory Sentence 3)\\nH: directly overcome resistance caused by the HER2 V777L mutation (from Explanatory Sentence 3)\\nI: overcoming treatment resistance (from Explanatory Sentence 3 and 4)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(irreversible inhibitor targeted to the HER2 kinase domain, overcome trastuzumab resistance induced by a HER2-activating mutation)\\n--------\\nImplies(C, D)\\nImplies(HER2 V777L mutation, trastuzumab resistance)\\n--------\\nImplies(E, Not(D))\\nImplies(trastuzumab binds to the extracellular kinase domain, Not(trastuzumab resistance))\\n--------\\nImplies(F, C)\\nImplies(mutation in the intracellular kinase domain, HER2 V777L mutation)\\n--------\\nImplies(G, H)\\nImplies(targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor, directly overcome resistance caused by the HER2 V777L mutation)\\n--------\\nImplies(H, I)\\nImplies(directly overcome resistance caused by the HER2 V777L mutation, overcoming treatment resistance)\\n--------\\nImplies(C, I)\\nImplies(HER2 V777L mutation, overcoming treatment resistance)\\n--------\\n\\nDerived Implications:\\nImplies(C, Not(E))\\nImplies(HER2 V777L mutation, Not(trastuzumab binds to the extracellular kinase domain))\\n--------\\nImplies(Not(I), Not(G))\\nImplies(Not(overcoming treatment resistance), Not(targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor))\\n--------\\nImplies(F, D)\\nImplies(mutation in the intracellular kinase domain, trastuzumab resistance)\\n--------\\nImplies(E, Not(C))\\nImplies(trastuzumab binds to the extracellular kinase domain, Not(HER2 V777L mutation))\\n--------\\nImplies(E, Not(F))\\nImplies(trastuzumab binds to the extracellular kinase domain, Not(mutation in the intracellular kinase domain))\\n--------\\nImplies(F, Not(E))\\nImplies(mutation in the intracellular kinase domain, Not(trastuzumab binds to the extracellular kinase domain))\\n--------\\nImplies(F, I)\\nImplies(mutation in the intracellular kinase domain, overcoming treatment resistance)\\n--------\\nImplies(Not(D), Not(F))\\nImplies(Not(trastuzumab resistance), Not(mutation in the intracellular kinase domain))\\n--------\\nImplies(Not(I), Not(F))\\nImplies(Not(overcoming treatment resistance), Not(mutation in the intracellular kinase domain))\\n--------\\nImplies(G, I)\\nImplies(targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor, overcoming treatment resistance)\\n--------\\n'}",
            "5 iteration: {'syntactic validity': True, 'error code': '(* Explanation 3 provides a logical relation Implies(F, G), which states that targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor directly overcomes resistance caused by the HER2 V777L mutation. *)\\n(* Explanation 4 provides a logical relation Implies(I, J), which states that overcoming resistance caused by the HER2 V777L mutation implies overcoming treatment resistance. *)\\n(* From Explanation 3, we have that targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor directly contributes to overcoming treatment resistance. *)\\n(* Therefore, we can infer that targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance. *)\\nthen have \"\u2203x e. Targeting x \u2227 TyrosineKinaseInhibitor x \u2227 Irreversible x \u2227 Overcome e \u2227 Agent e x \u2227 Patient e y\" sledgehammer', 'solving time': 103.59935450553894, 'proof tactics': [], 'code': 'theory clinical_104_5\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  Irreversible :: \"entity \u21d2 bool\"\\n  TargetedTo :: \"entity \u21d2 entity \u21d2 bool\"\\n  HER2KinaseDomain :: \"entity \u21d2 bool\"\\n  TrastuzumabResistance :: \"entity \u21d2 bool\"\\n  HER2ActivatingMutation :: \"entity \u21d2 bool\"\\n  Overcome :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  HER2V777L :: \"entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Bind :: \"event \u21d2 bool\"\\n  ExtracellularKinaseDomain :: \"entity \u21d2 bool\"\\n  IntracellularKinaseDomain :: \"entity \u21d2 bool\"\\n  Targeting :: \"entity \u21d2 bool\"\\n  HERV777LMutation :: \"entity \u21d2 bool\"\\n  TyrosineKinaseInhibitor :: \"entity \u21d2 bool\"\\n  Contribute :: \"event \u21d2 bool\"\\n  TreatmentResistance :: \"entity \u21d2 bool\"\\n  Implies :: \"event \u21d2 event \u21d2 bool\"\\n\\n(* Explanation 1: An irreversible inhibitor that is targeted to the HER2 kinase domain should overcome trastuzumab resistance that has been induced by a HER2-activating mutation. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. Inhibitor x \u2227 Irreversible x \u2227 TargetedTo x y \u2227 HER2KinaseDomain y \u2227 TrastuzumabResistance z \u2227 HER2ActivatingMutation z \u2227 Overcome e \u2227 Agent e x \u2227 Patient e z\"\\n\\n(* Explanation 2: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. HER2V777L x \u2227 Resistance y \u2227 Trastuzumab z \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Bind e2 \u2227 Agent e2 z \u2227 Patient e2 y \u2227 ExtracellularKinaseDomain y \u2227 IntracellularKinaseDomain x\"\\n\\n(* Explanation 3: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor can directly overcome the resistance caused by the HER2 V777L mutation, and this action directly contributes to overcoming treatment resistance. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. Targeting x \u2227 HERV777LMutation y \u2227 TyrosineKinaseInhibitor x \u2227 Irreversible x \u2227 Resistance z \u2227 HER2V777LMutation z \u2227 Overcome e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 Contribute e2 \u2227 Agent e2 x \u2227 Patient e2 y \u2227 TreatmentResistance y\"\\n\\n(* Explanation 4: Overcoming the resistance caused by the HER2 V777L mutation implies overcoming treatment resistance. *)\\naxiomatization where\\n  explanation_4: \"\u2200x y e1 e2. Resistance x \u2227 HER2V777LMutation x \u2227 TreatmentResistance y \u2227 Overcome e1 \u2227 Agent e1 x \u2227 Overcome e2 \u2227 Agent e2 y \u27f6 Implies e1 e2\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"HERV777LMutation y \u2227 TreatmentResistance y\"\\n  (* Hypothesis: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance. *)\\n  shows \"\u2203x y e. Targeting x \u2227 HERV777LMutation y \u2227 TyrosineKinaseInhibitor x \u2227 Irreversible x \u2227 Overcome e \u2227 Agent e x \u2227 Patient e y \u2227 TreatmentResistance y\"\\nproof -\\n  (* From the premise, we have known information about the HER V777L mutation and treatment resistance. *)\\n  from asm have \"HERV777LMutation y \u2227 TreatmentResistance y\" <ATP>\\n  (* Explanation 3 provides a logical relation Implies(F, G), which states that targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor directly overcomes resistance caused by the HER2 V777L mutation. *)\\n  (* Explanation 4 provides a logical relation Implies(I, J), which states that overcoming resistance caused by the HER2 V777L mutation implies overcoming treatment resistance. *)\\n  (* From Explanation 3, we have that targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor directly contributes to overcoming treatment resistance. *)\\n  (* Therefore, we can infer that targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance. *)\\n  then have \"\u2203x e. Targeting x \u2227 TyrosineKinaseInhibitor x \u2227 Irreversible x \u2227 Overcome e \u2227 Agent e x \u2227 Patient e y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: irreversible inhibitor targeted to the HER2 kinase domain (from Explanatory Sentence 1)\\nB: overcome trastuzumab resistance induced by a HER2-activating mutation (from Explanatory Sentence 1)\\nC: HER2 V777L causes resistance to trastuzumab (from Explanatory Sentence 2)\\nD: trastuzumab binds to the extracellular kinase domain (from Explanatory Sentence 2)\\nE: mutation is in the intracellular kinase domain (from Explanatory Sentence 2)\\nF: targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor (from Explanatory Sentence 3)\\nG: directly overcome resistance caused by the HER2 V777L mutation (from Explanatory Sentence 3)\\nH: directly contributes to overcoming treatment resistance (from Explanatory Sentence 3)\\nI: overcoming resistance caused by the HER2 V777L mutation (from Explanatory Sentence 4)\\nJ: overcoming treatment resistance (from Explanatory Sentence 4)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(irreversible inhibitor targeted to the HER2 kinase domain, overcome trastuzumab resistance induced by a HER2-activating mutation)\\n--------\\nImplies(C, D)\\nImplies(HER2 V777L causes resistance to trastuzumab, trastuzumab binds to the extracellular kinase domain)\\n--------\\nImplies(C, E)\\nImplies(HER2 V777L causes resistance to trastuzumab, mutation is in the intracellular kinase domain)\\n--------\\nImplies(F, G)\\nImplies(targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor, directly overcome resistance caused by the HER2 V777L mutation)\\n--------\\nImplies(G, H)\\nImplies(directly overcome resistance caused by the HER2 V777L mutation, directly contributes to overcoming treatment resistance)\\n--------\\nImplies(I, J)\\nImplies(overcoming resistance caused by the HER2 V777L mutation, overcoming treatment resistance)\\n--------\\n\\nDerived Implications:\\nImplies(F, H)\\nImplies(targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor, directly contributes to overcoming treatment resistance)\\n--------\\nImplies(Not(H), Not(F))\\nImplies(Not(directly contributes to overcoming treatment resistance), Not(targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor))\\n--------\\n'}",
            "6 iteration: {'syntactic validity': True, 'error code': '(* There is a logical relation Implies(F, G), which states that targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor implies directly overcoming the resistance caused by the HER2 V777L mutation. *)\\n(* Since we have F from the premise, we can infer G. *)\\nthen have \"Overcome e \u2227 Agent e x \u2227 Patient e y\" sledgehammer', 'solving time': 103.28158950805664, 'proof tactics': [], 'code': 'theory clinical_104_6\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  TargetedTo :: \"entity \u21d2 entity \u21d2 bool\"\\n  HER2_Kinase_Domain :: \"entity \u21d2 bool\"\\n  Trastuzumab_Resistance :: \"entity \u21d2 bool\"\\n  HER2_Activating_Mutation :: \"entity \u21d2 bool\"\\n  Overcome :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  HER2_V777L :: \"entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Targeting :: \"entity \u21d2 bool\"\\n  HER_V777L_Mutation :: \"entity \u21d2 bool\"\\n  Tyrosine_Kinase_Inhibitor :: \"entity \u21d2 bool\"\\n  HER2_V777L_Mutation :: \"entity \u21d2 bool\"\\n  Treatment_Resistance :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: An irreversible inhibitor that is targeted to the HER2 kinase domain should overcome trastuzumab resistance that has been induced by a HER2-activating mutation. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. Inhibitor x \u2227 TargetedTo x y \u2227 HER2_Kinase_Domain y \u2227 Trastuzumab_Resistance z \u2227 HER2_Activating_Mutation z \u2227 Overcome e \u2227 Agent e x \u2227 Patient e z\"\\n\\n(* Explanation 2: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y e. HER2_V777L x \u2227 Trastuzumab y \u2227 Resistance y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\"\\n\\n(* Explanation 3: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor can directly overcome the resistance caused by the HER2 V777L mutation, and this action is a necessary step in overcoming treatment resistance. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. Targeting x \u2227 HER_V777L_Mutation y \u2227 Tyrosine_Kinase_Inhibitor x \u2227 Resistance z \u2227 HER2_V777L_Mutation y \u2227 Cause e1 \u2227 Agent e1 y \u2227 Patient e1 z \u2227 Overcome e2 \u2227 Agent e2 x \u2227 Patient e2 z\"\\n\\n(* Explanation 4: Directly overcoming the resistance caused by the HER2 V777L mutation implies overcoming treatment resistance. *)\\naxiomatization where\\n  explanation_4: \"\u2200x y e1 e2. Resistance x \u2227 HER2_V777L_Mutation y \u2227 Cause e1 \u2227 Agent e1 y \u2227 Patient e1 x \u2227 Overcome e2 \u2227 Agent e2 x \u27f6 Overcome e2 \u2227 Treatment_Resistance x\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Targeting x \u2227 HER_V777L_Mutation y \u2227 Tyrosine_Kinase_Inhibitor x\"\\n  (* Hypothesis: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance. *)\\n  shows \"\u2203x y e. Targeting x \u2227 HER_V777L_Mutation y \u2227 Tyrosine_Kinase_Inhibitor x \u2227 Overcome e \u2227 Agent e x \u2227 Patient e y\"\\nproof -\\n  (* From the premise, we have known information about targeting, HER V777L mutation, and tyrosine kinase inhibitor. *)\\n  from asm have \"Targeting x \u2227 HER_V777L_Mutation y \u2227 Tyrosine_Kinase_Inhibitor x\" <ATP>\\n  (* There is a logical relation Implies(F, G), which states that targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor implies directly overcoming the resistance caused by the HER2 V777L mutation. *)\\n  (* Since we have F from the premise, we can infer G. *)\\n  then have \"Overcome e \u2227 Agent e x \u2227 Patient e y\" <ATP>\\n  (* There is another logical relation Implies(G, I), which states that directly overcoming the resistance caused by the HER2 V777L mutation implies overcoming treatment resistance. *)\\n  (* Since we have G, we can infer I. *)\\n  then have \"Overcome e\" <ATP>\\n  (* Therefore, we can conclude the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: irreversible inhibitor targeted to the HER2 kinase domain (from Explanatory Sentence 1)\\nB: overcome trastuzumab resistance induced by a HER2-activating mutation (from Explanatory Sentence 1)\\nC: HER2 V777L causes resistance to trastuzumab (from Explanatory Sentence 2)\\nD: trastuzumab binds to the extracellular kinase domain (from Explanatory Sentence 2)\\nE: mutation is in the intracellular kinase domain (from Explanatory Sentence 2)\\nF: targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor (from Explanatory Sentence 3)\\nG: directly overcome the resistance caused by the HER2 V777L mutation (from Explanatory Sentence 3)\\nH: necessary step in overcoming treatment resistance (from Explanatory Sentence 3)\\nI: overcoming treatment resistance (from Explanatory Sentence 4)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(irreversible inhibitor targeted to the HER2 kinase domain, overcome trastuzumab resistance induced by a HER2-activating mutation)\\n--------\\nImplies(C, D)\\nImplies(HER2 V777L causes resistance to trastuzumab, trastuzumab binds to the extracellular kinase domain)\\n--------\\nImplies(C, E)\\nImplies(HER2 V777L causes resistance to trastuzumab, mutation is in the intracellular kinase domain)\\n--------\\nImplies(F, G)\\nImplies(targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor, directly overcome the resistance caused by the HER2 V777L mutation)\\n--------\\nImplies(G, H)\\nImplies(directly overcome the resistance caused by the HER2 V777L mutation, necessary step in overcoming treatment resistance)\\n--------\\nImplies(G, I)\\nImplies(directly overcome the resistance caused by the HER2 V777L mutation, overcoming treatment resistance)\\n--------\\n\\nDerived Implications:\\nImplies(Not(I), Not(F))\\nImplies(Not(overcoming treatment resistance), Not(targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor))\\n--------\\nImplies(F, H)\\nImplies(targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor, necessary step in overcoming treatment resistance)\\n--------\\nImplies(Not(H), Not(F))\\nImplies(Not(necessary step in overcoming treatment resistance), Not(targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor))\\n--------\\nImplies(F, I)\\nImplies(targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor, overcoming treatment resistance)\\n--------\\n'}",
            "7 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_104_7\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  TargetedTo :: \"entity \u21d2 entity \u21d2 bool\"\\n  HER2_Kinase_Domain :: \"entity \u21d2 bool\"\\n  Trastuzumab_Resistance :: \"entity \u21d2 bool\"\\n  HER2_Activating_Mutation :: \"entity \u21d2 bool\"\\n  Overcome :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  InducedBy :: \"event \u21d2 entity \u21d2 bool\"\\n  HER2_V777L :: \"entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Targeting :: \"entity \u21d2 bool\"\\n  HER_V777L_Mutation :: \"entity \u21d2 bool\"\\n  Tyrosine_Kinase_Inhibitor :: \"entity \u21d2 bool\"\\n  NecessaryStep :: \"event \u21d2 bool\"\\n  Treatment_Resistance :: \"event \u21d2 bool\"\\n  Implies :: \"event \u21d2 event \u21d2 bool\"\\n  Aimed :: \"event \u21d2 bool\"\\n  CriticalFactor :: \"event \u21d2 bool\"\\n  HER2_V777L_Mutation :: \"entity \u21d2 bool\"  (* Added missing consts definition *)\\n\\n(* Explanation 1: An irreversible inhibitor that is targeted to the HER2 kinase domain should overcome trastuzumab resistance that has been induced by a HER2-activating mutation. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. Inhibitor x \u2227 TargetedTo x y \u2227 HER2_Kinase_Domain y \u2227 Trastuzumab_Resistance z \u2227 HER2_Activating_Mutation z \u2227 Overcome e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 InducedBy e2 z\"\\n\\n(* Explanation 2: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y e. HER2_V777L x \u2227 Resistance y \u2227 Trastuzumab y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\"\\n\\n(* Explanation 3: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor can directly overcome the resistance caused by the HER2 V777L mutation, and this action is a necessary step in overcoming treatment resistance. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. Targeting x \u2227 HER_V777L_Mutation y \u2227 Tyrosine_Kinase_Inhibitor x \u2227 Resistance z \u2227 HER2_V777L_Mutation z \u2227 Overcome e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 NecessaryStep e2 \u2227 Overcome e2 \u2227 Treatment_Resistance e2\"\\n\\n(* Explanation 4: Directly overcoming the resistance caused by the HER2 V777L mutation implies overcoming treatment resistance. *)\\naxiomatization where\\n  explanation_4: \"\u2200x y e1 e2. Resistance x \u2227 HER2_V777L_Mutation x \u2227 Overcome e1 \u2227 Agent e1 x \u2227 Treatment_Resistance y \u2227 Overcome e2 \u2227 (Agent e2 x \u27f6 Implies e1 e2)\"\\n\\n(* Explanation 5: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor is specifically aimed at overcoming the resistance caused by the HER2 V777L mutation, which is a critical factor in overcoming treatment resistance. *)\\naxiomatization where\\n  explanation_5: \"\u2203x y z e1 e2. Targeting x \u2227 HER_V777L_Mutation y \u2227 Tyrosine_Kinase_Inhibitor x \u2227 Resistance z \u2227 HER2_V777L_Mutation z \u2227 Aimed e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 CriticalFactor e2 \u2227 Overcome e2 \u2227 Treatment_Resistance e2\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Targeting x \u2227 HER_V777L_Mutation y \u2227 Tyrosine_Kinase_Inhibitor x\"\\n  (* Hypothesis: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance. *)\\n  shows \"\u2203x y e. Targeting x \u2227 HER_V777L_Mutation y \u2227 Tyrosine_Kinase_Inhibitor x \u2227 Overcome e \u2227 Agent e x \u2227 Patient e y\"\\nproof -\\n  (* From the premise, we have known information about targeting, HER V777L mutation, and tyrosine kinase inhibitor. *)\\n  from asm have \"Targeting x \u2227 HER_V777L_Mutation y \u2227 Tyrosine_Kinase_Inhibitor x\" <ATP>\\n  (* There is a logical relation Implies(F, G), which states that targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor implies directly overcoming the resistance caused by the HER2 V777L mutation. *)\\n  (* We have F from the premise, so we can infer G. *)\\n  then have \"Overcome e \u2227 Agent e x \u2227 Patient e y\" <ATP>\\n  (* There is another logical relation Implies(G, H), which states that directly overcoming the resistance caused by the HER2 V777L mutation implies overcoming treatment resistance. *)\\n  (* Since we have G, we can infer H. *)\\n  then have \"Overcome e\" <ATP>\\n  (* Therefore, we can conclude the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: irreversible inhibitor targeted to the HER2 kinase domain (from Explanatory Sentence 1)\\nB: overcome trastuzumab resistance induced by a HER2-activating mutation (from Explanatory Sentence 1)\\nC: HER2 V777L causes resistance to trastuzumab (from Explanatory Sentence 2)\\nD: trastuzumab binds to the extracellular kinase domain (from Explanatory Sentence 2)\\nE: mutation is in the intracellular kinase domain (from Explanatory Sentence 2)\\nF: targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor (from Explanatory Sentence 3)\\nG: directly overcome the resistance caused by the HER2 V777L mutation (from Explanatory Sentence 3)\\nH: overcoming treatment resistance (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(irreversible inhibitor targeted to the HER2 kinase domain, overcome trastuzumab resistance induced by a HER2-activating mutation)\\n--------\\nImplies(C, D)\\nImplies(HER2 V777L causes resistance to trastuzumab, trastuzumab binds to the extracellular kinase domain)\\n--------\\nImplies(C, E)\\nImplies(HER2 V777L causes resistance to trastuzumab, mutation is in the intracellular kinase domain)\\n--------\\nImplies(F, G)\\nImplies(targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor, directly overcome the resistance caused by the HER2 V777L mutation)\\n--------\\nImplies(G, H)\\nImplies(directly overcome the resistance caused by the HER2 V777L mutation, overcoming treatment resistance)\\n--------\\nImplies(F, G) and Implies(G, H)\\nImplies(directly overcome the resistance caused by the HER2 V777L mutation, overcoming treatment resistance)\\n--------\\n\\nDerived Implications:\\nImplies(F, H)\\nImplies(targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor, overcoming treatment resistance)\\n--------\\nImplies(Not(H), Not(F))\\nImplies(Not(overcoming treatment resistance), Not(targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor))\\n--------\\n'}",
            "8 iteration: {'syntactic validity': True, 'error code': '(* Explanation 3 provides a logical relation Implies(F, G), which states that targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor directly overcomes the resistance caused by the HER2 V777L mutation. *)\\n(* Explanation 4 provides a logical relation Implies(G, H), which states that directly overcoming the resistance caused by the HER2 V777L mutation implies overcoming treatment resistance. *)\\n(* Combining these, we have the derived implication Implies(F, H), which states that targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor implies overcoming treatment resistance. *)\\n(* Since we have Tyrosine_Kinase_Inhibitor x and HER_V777L_Mutation y, we can infer targeting and overcoming treatment resistance. *)\\nthen have \"Targeting x \u2227 Overcome e \u2227 Agent e x \u2227 Patient e y \u2227 Treatment_Resistance y\" sledgehammer', 'solving time': 103.3055260181427, 'proof tactics': [], 'code': 'theory clinical_104_8\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  Targeted :: \"entity \u21d2 entity \u21d2 bool\"\\n  HER2_Kinase_Domain :: \"entity \u21d2 bool\"\\n  Trastuzumab_Resistance :: \"entity \u21d2 bool\"\\n  HER2_Activating_Mutation :: \"entity \u21d2 bool\"\\n  Overcome :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  HER2_V777L :: \"entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  HER_V777L_Mutation :: \"entity \u21d2 bool\"\\n  Tyrosine_Kinase_Inhibitor :: \"entity \u21d2 bool\"\\n  Treatment_Resistance :: \"entity \u21d2 bool\"\\n  Targeting :: \"entity \u21d2 bool\"\\n  HER2_V777L_Mutation :: \"entity \u21d2 bool\"  (* Added missing consts definition *)\\n\\n(* Explanation 1: An irreversible inhibitor that is targeted to the HER2 kinase domain should overcome trastuzumab resistance that has been induced by a HER2-activating mutation. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. Inhibitor x \u2227 Targeted x y \u2227 HER2_Kinase_Domain y \u2227 Trastuzumab_Resistance z \u2227 HER2_Activating_Mutation z \u2227 Overcome e \u2227 Agent e x \u2227 Patient e z\"\\n\\n(* Explanation 2: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y e. HER2_V777L x \u2227 Trastuzumab y \u2227 Resistance y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\"\\n\\n(* Explanation 3: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor can directly overcome the resistance caused by the HER2 V777L mutation, and this action is a necessary step in overcoming treatment resistance. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. Targeting x \u2227 HER_V777L_Mutation y \u2227 Tyrosine_Kinase_Inhibitor x \u2227 Resistance z \u2227 HER2_V777L_Mutation z \u2227 Cause e1 \u2227 Agent e1 z \u2227 Patient e1 z \u2227 Overcome e2 \u2227 Agent e2 x \u2227 Patient e2 z\"\\n\\n(* Explanation 4: Directly overcoming the resistance caused by the HER2 V777L mutation implies overcoming treatment resistance. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y e1 e2. Resistance x \u2227 HER2_V777L_Mutation x \u2227 Cause e1 \u2227 Agent e1 x \u2227 Overcome e2 \u2227 Agent e2 x \u2227 Treatment_Resistance y \u27f6 Overcome e2 \u2227 Agent e2 x \u2227 Patient e2 y\"\\n\\n(* Explanation 5: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor is specifically aimed at overcoming the resistance caused by the HER2 V777L mutation, which is a critical factor in overcoming treatment resistance. *)\\naxiomatization where\\n  explanation_5: \"\u2203x y z e1 e2. Targeting x \u2227 HER_V777L_Mutation y \u2227 Tyrosine_Kinase_Inhibitor x \u2227 Resistance z \u2227 HER2_V777L_Mutation z \u2227 Cause e1 \u2227 Agent e1 z \u2227 Patient e1 z \u2227 Overcome e2 \u2227 Agent e2 x \u2227 Patient e2 z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"HER_V777L_Mutation y \u2227 Tyrosine_Kinase_Inhibitor x\"\\n  (* Hypothesis: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance. *)\\n  shows \"\u2203x y e. Targeting x \u2227 HER_V777L_Mutation y \u2227 Tyrosine_Kinase_Inhibitor x \u2227 Overcome e \u2227 Agent e x \u2227 Patient e y \u2227 Treatment_Resistance y\"\\nproof -\\n  (* From the premise, we have known information about HER_V777L_Mutation and Tyrosine_Kinase_Inhibitor. *)\\n  from asm have \"HER_V777L_Mutation y \u2227 Tyrosine_Kinase_Inhibitor x\" <ATP>\\n  (* Explanation 3 provides a logical relation Implies(F, G), which states that targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor directly overcomes the resistance caused by the HER2 V777L mutation. *)\\n  (* Explanation 4 provides a logical relation Implies(G, H), which states that directly overcoming the resistance caused by the HER2 V777L mutation implies overcoming treatment resistance. *)\\n  (* Combining these, we have the derived implication Implies(F, H), which states that targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor implies overcoming treatment resistance. *)\\n  (* Since we have Tyrosine_Kinase_Inhibitor x and HER_V777L_Mutation y, we can infer targeting and overcoming treatment resistance. *)\\n  then have \"Targeting x \u2227 Overcome e \u2227 Agent e x \u2227 Patient e y \u2227 Treatment_Resistance y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: irreversible inhibitor targeted to the HER2 kinase domain (from Explanatory Sentence 1)\\nB: overcome trastuzumab resistance induced by a HER2-activating mutation (from Explanatory Sentence 1)\\nC: HER2 V777L causes resistance to trastuzumab (from Explanatory Sentence 2)\\nD: trastuzumab binds to the extracellular kinase domain (from Explanatory Sentence 2)\\nE: mutation is in the intracellular kinase domain (from Explanatory Sentence 2)\\nF: targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor (from Explanatory Sentence 3)\\nG: directly overcome the resistance caused by the HER2 V777L mutation (from Explanatory Sentence 3)\\nH: overcoming treatment resistance (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(irreversible inhibitor targeted to the HER2 kinase domain, overcome trastuzumab resistance induced by a HER2-activating mutation)\\n--------\\nImplies(C, D)\\nImplies(HER2 V777L causes resistance to trastuzumab, trastuzumab binds to the extracellular kinase domain)\\n--------\\nImplies(C, E)\\nImplies(HER2 V777L causes resistance to trastuzumab, mutation is in the intracellular kinase domain)\\n--------\\nImplies(F, G)\\nImplies(targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor, directly overcome the resistance caused by the HER2 V777L mutation)\\n--------\\nImplies(G, H)\\nImplies(directly overcome the resistance caused by the HER2 V777L mutation, overcoming treatment resistance)\\n--------\\nImplies(F, G) and Implies(G, H)\\nImplies(directly overcome the resistance caused by the HER2 V777L mutation, overcoming treatment resistance)\\n--------\\n\\nDerived Implications:\\nImplies(F, H)\\nImplies(targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor, overcoming treatment resistance)\\n--------\\nImplies(Not(H), Not(F))\\nImplies(Not(overcoming treatment resistance), Not(targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor))\\n--------\\n'}",
            "9 iteration: {'syntactic validity': True, 'error code': '(* Explanation 3 provides a logical relation: targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor can directly overcome the resistance caused by the HER2 V777L mutation. *)\\n(* This action is a necessary step in overcoming treatment resistance. *)\\n(* We have the logical relation Implies(F, G) and Implies(G, H), which implies Implies(F, H). *)\\n(* Explanation 5 states that targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor is specifically aimed at overcoming the resistance caused by the HER2 V777L mutation, which is a critical factor in overcoming treatment resistance. *)\\n(* We have the logical relation Implies(F, I). *)\\n(* From these, we can infer that targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor is a necessary step and a critical factor in overcoming treatment resistance. *)\\nthen have \"\u2203x e. Targeting x \u2227 HER_V777L_Mutation y \u2227 Tyrosine_Kinase_Inhibitor x \u2227 Irreversible x \u2227 Overcome e \u2227 Agent e x \u2227 Patient e y \u2227 Treatment_Resistance y\" sledgehammer', 'solving time': 103.3438024520874, 'proof tactics': [], 'code': 'theory clinical_104_9\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  Irreversible :: \"entity \u21d2 bool\"\\n  Targeted :: \"entity \u21d2 entity \u21d2 bool\"\\n  HER2_Kinase_Domain :: \"entity \u21d2 bool\"\\n  Overcome :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Trastuzumab_Resistance :: \"entity \u21d2 bool\"\\n  Induced :: \"entity \u21d2 entity \u21d2 bool\"\\n  HER2_V777L :: \"entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Bind :: \"entity \u21d2 entity \u21d2 bool\"\\n  Mutation_In :: \"entity \u21d2 bool\"\\n  Targeting :: \"entity \u21d2 bool\"\\n  HER_V777L_Mutation :: \"entity \u21d2 bool\"\\n  Tyrosine_Kinase_Inhibitor :: \"entity \u21d2 bool\"\\n  Necessary_Step :: \"event \u21d2 entity \u21d2 bool\"\\n  Treatment_Resistance :: \"entity \u21d2 bool\"\\n  Critical_Factor :: \"event \u21d2 entity \u21d2 bool\"\\n  Aim :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: An irreversible inhibitor that is targeted to the HER2 kinase domain should overcome trastuzumab resistance that has been induced by a HER2-activating mutation. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. Inhibitor x \u2227 Irreversible x \u2227 Targeted x y \u2227 HER2_Kinase_Domain y \u2227 Overcome e \u2227 Agent e x \u2227 Trastuzumab_Resistance z \u2227 Induced z HER2_Activating_Mutation\"\\n\\n(* Explanation 2: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e. HER2_V777L x \u2227 Resistance y \u2227 Trastuzumab z \u2227 Cause e \u2227 Agent e x \u2227 Patient e y \u2227 Bind z Extracellular_Kinase_Domain \u2227 Mutation_In Intracellular_Kinase_Domain\"\\n\\n(* Explanation 3: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor can directly overcome the resistance caused by the HER2 V777L mutation, and this action is a necessary step in overcoming treatment resistance. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. Targeting x \u2227 HER_V777L_Mutation y \u2227 Tyrosine_Kinase_Inhibitor x \u2227 Irreversible x \u2227 Overcome e1 \u2227 Agent e1 x \u2227 Resistance z \u2227 Cause e2 \u2227 Agent e2 y \u2227 Patient e2 z \u2227 Necessary_Step e1 z\"\\n\\n(* Explanation 4: Directly overcoming the resistance caused by the HER2 V777L mutation is a critical factor in overcoming treatment resistance. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y e1 e2. Overcome e1 \u2227 Resistance x \u2227 Cause e2 \u2227 Agent e2 y \u2227 Patient e2 x \u2227 Critical_Factor e1 x\"\\n\\n(* Explanation 5: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor is specifically aimed at overcoming the resistance caused by the HER2 V777L mutation, which is a critical factor in overcoming treatment resistance. *)\\naxiomatization where\\n  explanation_5: \"\u2203x y z e1 e2. Targeting x \u2227 HER_V777L_Mutation y \u2227 Tyrosine_Kinase_Inhibitor x \u2227 Irreversible x \u2227 Aim e1 \u2227 Overcome e2 \u2227 Agent e2 x \u2227 Resistance z \u2227 Cause e1 \u2227 Agent e1 y \u2227 Patient e1 z \u2227 Critical_Factor e2 z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"HER_V777L_Mutation y \u2227 Treatment_Resistance y\"\\n  (* Hypothesis: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance. *)\\n  shows \"\u2203x y e. Targeting x \u2227 HER_V777L_Mutation y \u2227 Tyrosine_Kinase_Inhibitor x \u2227 Irreversible x \u2227 Overcome e \u2227 Agent e x \u2227 Patient e y \u2227 Treatment_Resistance y\"\\nproof -\\n  (* From the premise, we have known information about HER_V777L_Mutation and Treatment_Resistance. *)\\n  from asm have \"HER_V777L_Mutation y \u2227 Treatment_Resistance y\" <ATP>\\n  (* Explanation 3 provides a logical relation: targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor can directly overcome the resistance caused by the HER2 V777L mutation. *)\\n  (* This action is a necessary step in overcoming treatment resistance. *)\\n  (* We have the logical relation Implies(F, G) and Implies(G, H), which implies Implies(F, H). *)\\n  (* Explanation 5 states that targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor is specifically aimed at overcoming the resistance caused by the HER2 V777L mutation, which is a critical factor in overcoming treatment resistance. *)\\n  (* We have the logical relation Implies(F, I). *)\\n  (* From these, we can infer that targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor is a necessary step and a critical factor in overcoming treatment resistance. *)\\n  then have \"\u2203x e. Targeting x \u2227 HER_V777L_Mutation y \u2227 Tyrosine_Kinase_Inhibitor x \u2227 Irreversible x \u2227 Overcome e \u2227 Agent e x \u2227 Patient e y \u2227 Treatment_Resistance y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: irreversible inhibitor targeted to the HER2 kinase domain (from Explanatory Sentence 1)\\nB: overcome trastuzumab resistance induced by a HER2-activating mutation (from Explanatory Sentence 1)\\nC: HER2 V777L causes resistance to trastuzumab (from Explanatory Sentence 2)\\nD: trastuzumab binds to the extracellular kinase domain (from Explanatory Sentence 2)\\nE: mutation is in the intracellular kinase domain (from Explanatory Sentence 2)\\nF: targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor (from Explanatory Sentence 3)\\nG: directly overcome the resistance caused by the HER2 V777L mutation (from Explanatory Sentence 3)\\nH: necessary step in overcoming treatment resistance (from Explanatory Sentence 3)\\nI: critical factor in overcoming treatment resistance (from Explanatory Sentence 4 and 5)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(irreversible inhibitor targeted to the HER2 kinase domain, overcome trastuzumab resistance induced by a HER2-activating mutation)\\n--------\\nImplies(C, D)\\nImplies(HER2 V777L causes resistance to trastuzumab, trastuzumab binds to the extracellular kinase domain)\\n--------\\nImplies(C, E)\\nImplies(HER2 V777L causes resistance to trastuzumab, mutation is in the intracellular kinase domain)\\n--------\\nImplies(F, G)\\nImplies(targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor, directly overcome the resistance caused by the HER2 V777L mutation)\\n--------\\nImplies(G, H)\\nImplies(directly overcome the resistance caused by the HER2 V777L mutation, necessary step in overcoming treatment resistance)\\n--------\\nImplies(G, I)\\nImplies(directly overcome the resistance caused by the HER2 V777L mutation, critical factor in overcoming treatment resistance)\\n--------\\nImplies(F, I)\\nImplies(targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor, critical factor in overcoming treatment resistance)\\n--------\\n\\nDerived Implications:\\nImplies(F, H)\\nImplies(targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor, necessary step in overcoming treatment resistance)\\n--------\\nImplies(Not(H), Not(F))\\nImplies(Not(necessary step in overcoming treatment resistance), Not(targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor))\\n--------\\n'}",
            "10 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_104_10\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Inhibitor :: \"entity \u21d2 bool\"\\n  TargetedTo :: \"entity \u21d2 entity \u21d2 bool\"\\n  HER2_Kinase_Domain :: \"entity \u21d2 bool\"\\n  Trastuzumab_Resistance :: \"entity \u21d2 bool\"\\n  HER2_Activating_Mutation :: \"entity \u21d2 bool\"\\n  Overcome :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  InducedBy :: \"event \u21d2 entity \u21d2 bool\"\\n  HER2_V777L :: \"entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  Extracellular_Kinase_Domain :: \"entity \u21d2 bool\"\\n  Intracellular_Kinase_Domain :: \"entity \u21d2 bool\"\\n  Resistance :: \"event \u21d2 bool\"\\n  Cause :: \"event \u21d2 entity \u21d2 bool\"\\n  Bind :: \"event \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Targeting :: \"entity \u21d2 bool\"\\n  HER_V777L_Mutation :: \"entity \u21d2 bool\"\\n  Tyrosine_Kinase_Inhibitor :: \"entity \u21d2 bool\"\\n  HER2_V777L_Mutation :: \"entity \u21d2 bool\"\\n  NecessaryStep :: \"event \u21d2 event \u21d2 bool\"\\n  Treatment_Resistance :: \"entity \u21d2 bool\"\\n  CriticalFactor :: \"event \u21d2 event \u21d2 bool\"\\n  AimedAt :: \"event \u21d2 event \u21d2 bool\"\\n  RelatedTo :: \"event \u21d2 event \u21d2 bool\"\\n\\n(* Explanation 1: An irreversible inhibitor that is targeted to the HER2 kinase domain should overcome trastuzumab resistance that has been induced by a HER2-activating mutation. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. Inhibitor x \u2227 TargetedTo x y \u2227 HER2_Kinase_Domain y \u2227 Trastuzumab_Resistance z \u2227 HER2_Activating_Mutation z \u2227 Overcome e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 InducedBy e2 z\"\\n\\n(* Explanation 2: HER2 V777L may cause resistance to trastuzumab, as trastuzumab binds to the extracellular kinase domain, whereas the mutation is in the intracellular kinase domain. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. HER2_V777L x \u2227 Trastuzumab y \u2227 Extracellular_Kinase_Domain z \u2227 Intracellular_Kinase_Domain z \u2227 Resistance e1 \u2227 Cause e1 x \u2227 Patient e1 y \u2227 Bind e2 \u2227 Agent e2 y \u2227 Patient e2 z \u2227 In x z\"\\n\\n(* Explanation 3: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor can directly overcome the resistance caused by the HER2 V777L mutation, and this action is a necessary step in overcoming treatment resistance. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. Targeting x \u2227 HER_V777L_Mutation y \u2227 Tyrosine_Kinase_Inhibitor x \u2227 Resistance z \u2227 HER2_V777L_Mutation y \u2227 Overcome e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 Cause e2 y \u2227 NecessaryStep e2 e1\"\\n\\n(* Explanation 4: Directly overcoming the resistance caused by the HER2 V777L mutation is a critical factor in overcoming treatment resistance. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y e1 e2. Resistance x \u2227 HER2_V777L_Mutation y \u2227 Treatment_Resistance y \u2227 Overcome e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 CriticalFactor e2 e1\"\\n\\n(* Explanation 5: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor is specifically aimed at overcoming the resistance caused by the HER2 V777L mutation, which is a critical factor in overcoming treatment resistance. *)\\naxiomatization where\\n  explanation_5: \"\u2203x y z e1 e2. Targeting x \u2227 HER_V777L_Mutation y \u2227 Tyrosine_Kinase_Inhibitor x \u2227 Resistance z \u2227 HER2_V777L_Mutation y \u2227 Overcome e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 AimedAt e2 e1 \u2227 CriticalFactor e2 e1\"\\n\\n(* Explanation 6: Overcoming the resistance caused by the HER2 V777L mutation is directly related to overcoming overall treatment resistance. *)\\naxiomatization where\\n  explanation_6: \"\u2203x y e1 e2. Resistance x \u2227 HER2_V777L_Mutation y \u2227 Treatment_Resistance y \u2227 Overcome e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 RelatedTo e2 e1\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Targeting x \u2227 HER_V777L_Mutation y \u2227 Tyrosine_Kinase_Inhibitor x\"\\n  (* Hypothesis: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance. *)\\n  shows \"\u2203x y e. Targeting x \u2227 HER_V777L_Mutation y \u2227 Tyrosine_Kinase_Inhibitor x \u2227 Overcome e \u2227 Agent e x \u2227 Patient e y\"\\nproof -\\n  (* From the premise, we have known information about targeting, HER V777L mutation, and tyrosine kinase inhibitor. *)\\n  from asm have \"Targeting x \u2227 HER_V777L_Mutation y \u2227 Tyrosine_Kinase_Inhibitor x\" <ATP>\\n  (* There is a logical relation Implies(F, G), which states that targeting HER V777L mutation with an irreversible tyrosine kinase inhibitor implies directly overcoming resistance caused by HER2 V777L mutation. *)\\n  (* F is from explanatory sentence 3, G is from explanatory sentence 3. *)\\n  (* We already have F, so we can infer G. *)\\n  then have \"Overcome e \u2227 Agent e x \u2227 Patient e y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: irreversible inhibitor targeted to the HER2 kinase domain (from Explanatory Sentence 1)\\nB: overcome trastuzumab resistance induced by a HER2-activating mutation (from Explanatory Sentence 1)\\nC: HER2 V777L causes resistance to trastuzumab (from Explanatory Sentence 2)\\nD: trastuzumab binds to the extracellular kinase domain (from Explanatory Sentence 2)\\nE: mutation in the intracellular kinase domain (from Explanatory Sentence 2)\\nF: targeting HER V777L mutation with an irreversible tyrosine kinase inhibitor (from Explanatory Sentence 3)\\nG: directly overcome resistance caused by HER2 V777L mutation (from Explanatory Sentence 3)\\nH: necessary step in overcoming treatment resistance (from Explanatory Sentence 3)\\nI: critical factor in overcoming treatment resistance (from Explanatory Sentence 4)\\nJ: overcoming resistance caused by HER2 V777L mutation (from Explanatory Sentence 6)\\nK: overcoming overall treatment resistance (from Explanatory Sentence 6)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(irreversible inhibitor targeted to the HER2 kinase domain, overcome trastuzumab resistance induced by a HER2-activating mutation)\\n--------\\nImplies(C, D)\\nImplies(HER2 V777L causes resistance to trastuzumab, trastuzumab binds to the extracellular kinase domain)\\n--------\\nImplies(C, E)\\nImplies(HER2 V777L causes resistance to trastuzumab, mutation in the intracellular kinase domain)\\n--------\\nImplies(F, G)\\nImplies(targeting HER V777L mutation with an irreversible tyrosine kinase inhibitor, directly overcome resistance caused by HER2 V777L mutation)\\n--------\\nImplies(G, H)\\nImplies(directly overcome resistance caused by HER2 V777L mutation, necessary step in overcoming treatment resistance)\\n--------\\nImplies(G, I)\\nImplies(directly overcome resistance caused by HER2 V777L mutation, critical factor in overcoming treatment resistance)\\n--------\\nImplies(J, K)\\nImplies(overcoming resistance caused by HER2 V777L mutation, overcoming overall treatment resistance)\\n--------\\n\\nDerived Implications:\\nImplies(Not(I), Not(F))\\nImplies(Not(critical factor in overcoming treatment resistance), Not(targeting HER V777L mutation with an irreversible tyrosine kinase inhibitor))\\n--------\\nImplies(F, H)\\nImplies(targeting HER V777L mutation with an irreversible tyrosine kinase inhibitor, necessary step in overcoming treatment resistance)\\n--------\\nImplies(Not(H), Not(F))\\nImplies(Not(necessary step in overcoming treatment resistance), Not(targeting HER V777L mutation with an irreversible tyrosine kinase inhibitor))\\n--------\\nImplies(F, I)\\nImplies(targeting HER V777L mutation with an irreversible tyrosine kinase inhibitor, critical factor in overcoming treatment resistance)\\n--------\\n'}"
        ]
    }
}